Today: 21 May 2026

Michał Rogucki

HSBC share price steadies near highs as investors weigh new targets and Singapore sale talk

HSBC share price steadies near highs as investors weigh new targets and Singapore sale talk

HSBC shares rose 0.4% to 1,404 pence in early London trade Friday, staying near recent highs after annual results. The bank reported 2025 pretax profit of $29.9 billion, down 7% after one-off charges, and approved a fourth interim dividend of $0.45 per share. HSBC has started a sale process for its Singapore life insurance manufacturing unit, seeking a valuation above $1 billion.
27 February 2026
·
RELX share price today: stock edges up as buybacks keep traders watching

RELX share price today: stock edges up as buybacks keep traders watching

RELX shares rose 0.5% to 2,537.78 pence in early London trading Friday, following gains of 6.25% and 4.55% earlier in the week. The company repurchased 500,000 shares Thursday and is running a £450 million buyback through March 20. RELX also applied for a block listing of 80,000 shares for an employee plan, with admission expected March 2. The next trading update is set for April 23.
27 February 2026
·
Rolls-Royce share price ticks up as RR.L steadies after big buyback, outlook lift

Rolls-Royce share price ticks up as RR.L steadies after big buyback, outlook lift

Rolls-Royce shares rose 0.5% to 1,359 pence in early London trading Friday, after a 9.1% surge Thursday that helped lift the FTSE 100 to a record close. The company reported £3.46 billion in 2025 operating profit and launched a share buyback of up to £2.3 billion, set to run through December 23. Rolls-Royce forecasts £4.0–£4.2 billion profit and £3.6–£3.8 billion free cash flow in 2026.
27 February 2026
··
Brambles share price rises as buy-back filing shows steady pace — what to watch next for ASX:BXB

Brambles share price rises as buy-back filing shows steady pace — what to watch next for ASX:BXB

Brambles Ltd closed up 0.6% at A$25.08 after disclosing it bought back 101,855 shares for A$2.55 million on Feb. 25, with total repurchases reaching 12.56 million shares. The company cancelled the latest shares, leaving 1,357,878,736 on issue. Brambles has flagged it may pause buy-backs if conditions change. The interim dividend goes ex-dividend March 11, with payment due April 9.
27 February 2026
···
Telstra share price ends higher on buyback filing as dividend timeline sharpens focus

Telstra share price ends higher on buyback filing as dividend timeline sharpens focus

Telstra shares closed up 0.8% at A$5.18 Friday after the company bought back nearly 1.9 million shares for A$9.9 million, part of a buyback now totaling A$671 million. The stock traded ex-dividend this week, with a 10.5 cent interim payout due March 27. The S&P/ASX 200 rose 0.25%. Telstra recently raised its buyback cap to A$1.25 billion following a strong earnings report.
27 February 2026
···
PLS Group (ASX:PLS) share price pulls back after lithium shock from Zimbabwe

PLS Group (ASX:PLS) share price pulls back after lithium shock from Zimbabwe

PLS Group shares fell 1.1% to A$5.19 on Friday, retracing part of Thursday’s 8.3% jump. The decline followed Zimbabwe’s immediate suspension of raw mineral and lithium concentrate exports, which triggered supply concerns. China’s lithium carbonate futures surged over 6% after the ban. Zimbabwe exported over 1.1 million metric tons of lithium-bearing concentrate to China in 2025.
27 February 2026
···
Coles share price drops 7% after half-year profit slips — what ASX:COL investors watch next

Coles share price drops 7% after half-year profit slips — what ASX:COL investors watch next

Coles Group shares fell 7.3% to A$20.56 after reporting a half-year net profit drop of 11.3% to A$511 million, hit by A$235 million in legal costs. Underlying profit rose 12.5% to A$676 million. The board declared a 41-cent fully franked interim dividend, payable March 30. Coles flagged ongoing competition and legal risks, including an ACCC lawsuit over promotions.
27 February 2026
··
NAB share price cools after a $49.45 peak as ASIC update and RBA rate bets loom

NAB share price cools after a $49.45 peak as ASIC update and RBA rate bets loom

NAB shares closed nearly flat at A$49.02 on Friday after touching a 2026 high of A$49.45 earlier in the session. ASIC highlighted record penalties for bank misconduct, including actions against NAB. Traders are watching the March 17 RBA decision as January inflation remained high at 3.8%. NAB recently reported quarterly cash earnings of A$2.02 billion and announced leadership changes.
27 February 2026
··
Resideo (REZI) stock slips after 14% jump as investors digest 2026 outlook and spin-off plan

Resideo (REZI) stock slips after 14% jump as investors digest 2026 outlook and spin-off plan

Resideo shares fell 1.5% to $40.25 in early New York trading Thursday, after surging 14% the previous day. The company forecast 2026 adjusted EPS of $3.00–$3.20 and revenue of $7.8–$7.9 billion. Morgan Stanley raised its price target to $50 and reiterated an Overweight rating. Resideo reported a 2025 net loss of $527 million, citing a $1.59 billion payment to Honeywell.
26 February 2026
·
Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.
26 February 2026
··
1 … 19 20 21 22 23 … 27

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop